Bioventix PLC (FRA:51B)
Germany · Delayed Price · Currency is EUR | Market Cap | 105.39M -29.5% |
| Revenue (ttm) | 14.38M -8.2% |
| Net Income | 8.53M -5.2% |
| EPS | 1.61 -5.1% |
| Shares Out | n/a |
| PE Ratio | 12.36 |
| Forward PE | n/a |
| Dividend | 1.71 (8.79%) |
| Ex-Dividend Date | Apr 9, 2026 |
| Volume | n/a |
| Average Volume | 9 |
| Open | 19.00 |
| Previous Close | 19.00 |
| Day's Range | 19.00 - 19.00 |
| 52-Week Range | 14.90 - 35.00 |
| Beta | n/a |
| RSI | 53.21 |
| Earnings Date | Jun 26, 2026 |
About Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environ... [Read more]
Financial Performance
In fiscal year 2025, Bioventix's revenue was 13.12 million, a decrease of -3.61% compared to the previous year's 13.61 million. Earnings were 7.58 million, a decrease of -6.33%.
Financial numbers in GBP Financial StatementsNews
AIM Market Roundup: Angle, Coyngar, Light Science Technologies
Angle, Coyngar, Light Science Technologies are today's top risers, while BioVentix, Great Western Mining take the biggest fall on AIM